Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1962 1
1966 5
1970 1
1972 1
1974 2
1975 2
1976 1
1978 1
1979 2
1982 1
1983 2
1984 1
1987 2
1989 1
1990 5
1991 3
1992 2
1993 3
1994 3
1995 1
1996 6
1997 1
1998 5
1999 2
2000 2
2001 7
2002 3
2003 4
2004 7
2005 5
2006 6
2007 9
2008 12
2009 14
2010 6
2011 8
2012 15
2013 11
2014 17
2015 20
2016 22
2017 21
2018 14
2019 11
2020 20
2021 19
2022 12
2023 19
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Results by year

Filters applied: . Clear all
Page 1
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P. Herbst RS, et al. Among authors: gervais r. J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26. J Thorac Oncol. 2021. PMID: 34048946 Free article. Clinical Trial.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Among authors: gervais r. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Hyman DM, et al. Among authors: gervais r. N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. N Engl J Med. 2015. PMID: 26287849 Free PMC article. Clinical Trial.
[Oropharyngeal cancer].
Blanchard D, Rame JP, Louis MY, Gery B, Florescu C, de Raucourt D, Gervais R. Blanchard D, et al. Among authors: gervais r. Bull Cancer. 2014 May 1;101(5):429-37. doi: 10.1684/bdc.2014.1957. Bull Cancer. 2014. PMID: 24886893 Review. French.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Baize N, et al. Among authors: gervais r. Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7. Lancet Oncol. 2020. PMID: 32888454 Clinical Trial.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Zalcman G, et al. Among authors: gervais r. Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719230 Clinical Trial.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Hanna N, et al. Among authors: gervais r. J Clin Oncol. 2004 May 1;22(9):1589-97. doi: 10.1200/JCO.2004.08.163. J Clin Oncol. 2004. PMID: 15117980 Corrected and republished. Clinical Trial.
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, Silva M, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbaher Y, Neven A, Peters S. Girard N, et al. Among authors: gervais r. ESMO Open. 2023 Jun;8(3):101576. doi: 10.1016/j.esmoop.2023.101576. Epub 2023 Jun 6. ESMO Open. 2023. PMID: 37285717 Free PMC article. Clinical Trial.
[Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z, Berthet P, Polycarpe F, Dubos-Arvis C, Dô P, Gervais R. Neviere Z, et al. Among authors: gervais r. Rev Mal Respir. 2019 Feb;36(2):241-248. doi: 10.1016/j.rmr.2017.11.014. Epub 2019 Jan 24. Rev Mal Respir. 2019. PMID: 30686559 Review. French.
Foreword. Mechanisms underlying our cognitive functions.
Fourcaud-Trocmé N, Gervais R, Procyk E, Reynaud E. Fourcaud-Trocmé N, et al. Among authors: gervais r. J Physiol Paris. 2011 Jan-Jun;105(1-3):1. doi: 10.1016/j.jphysparis.2011.11.004. Epub 2011 Nov 12. J Physiol Paris. 2011. PMID: 22137467 No abstract available.
301 results